The effect of colchicine on micronutrients in children with newly diagnosed familial Mediterranean fever

Özge Kaba, Ayşe Tanatar, Rahime Koç, Şerife Gül Karadağ, Mustafa Çakan, Nuray Aktay Ayaz · 2026

Read The effect of colchicine on micronutrients in children with newly diagnosed familial Mediterranean fever by Özge Kaba, Ayşe Tanatar, Rahime Koç, Şerife Gül Karadağ, Mustafa Çakan, Nuray Aktay Ayaz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13224346.txt.

Introduction

Özge Kaba and co-authors track nutrient levels in children starting a standard drug for familial Mediterranean fever, in a 2026 study. The drug, colchicine, is the backbone of care for this inherited fever disease. It may also blunt vitamin uptake in the gut.

Forty-six newly diagnosed children were checked at the start and at three and six months on the drug. Fever and belly attacks were the common signs, and one gene fault dominated. By month six, hemoglobin and iron had risen as inflammation calmed, yet vitamin B12 and folate had fallen. The authors advise watching those vitamins during treatment, since their loss can itself cause anemia.

Catalog record

CREATORÖzge Kaba, Ayşe Tanatar, Rahime Koç, Şerife Gül Karadağ, Mustafa Çakan, Nuray Aktay Ayaz
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE17 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13224346

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The effect of colchicine on micronutrients in children with newly diagnosed familial Mediterranean fever Authors: Özge Kaba, Ayşe Tanatar, Rahime Koç, Şerife Gül Karadağ, Mustafa Çakan, Nuray Aktay Ayaz Published: 2026 ABSTRACT AbstractObjectivesColchicine is an essential component of familial Mediterranean fever (FMF) treatment. It is suggested that it may affect vitamin B12 levels by affecting intestinal absorption. This research focused on examining the impact of colchicine therapy on anemia parameters, as well as levels of vitamin B12 and folate in patients who have recently been diagnosed with FMF.MethodThis prospective cohort investigation assessed children diagnosed with FMF between October 2016 and February 2017, evaluating anemia parameters as well as vitamin B12 and folate levels at baseline and at the third and sixth months of colchicine therapy. The demographic data were recorded from patient files.ResultsForty-six children were involved. M694V was the most common mutation. The most common clinical findings were fever (87%), peritonitis (76.1%), and pleuritis (23.9%). The mean hemoglobin (p 0.027), iron (p < 0.001) levels were significantly increased, while the mean ferritin (p 0.002), vitamin B12 (p < 0.001) and folate (p 0.001) levels were decreased at the 6th month of colchicine treatment.ConclusionAlthough it has been determined that the suppressive effect of colchicine on inflammation improves anemia by increasing hemoglobin levels, it should also be kept in mind that it may cause a decrease in the levels of other variables that can cause anemia, such as vitamin B12 and folate.Keywords: Anemia, Colchicine, Familial Mediterranean Fever, Vitamin B12 deficiency Introduction Familial Mediterranean Fever (FMF) is a typical autoinflammatory disease that causes episodes of increased inflammation, which clinically present as fever, polyserositis, and arthritis [1]. However, subclinical inflammation may persist despite attack-free periods. Due to the relapsing and remitting nature of the disease, chronic anemia may also be observed in children with FMF. In addition to anemia of chronic disease, functional iron deficiency anemia can also occur due to altered iron metabolism caused by inflammatory factors such as hepcidin [2]. Levels of selected micronutrients, including folate and vitamin B12, which are important for growth and development, may also be affected by chronic inflammation, leading to decreased nutrient absorption and increased metabolic demands, thus contributing to anemia. Colchicine is the standard treatment modality in FMF [3]. Research suggests that long-term daily colchicine use significantly diminishes attack frequency, severity, and duration, thereby preventing the development of amyloidosis [4]. However, colchicine may cause various adverse effects, especially in rapidly proliferating tissues such as the gastrointestinal tract and bone marrow. Specifically, colchicine has been associated with leukopenia, thrombocytopenia, and aplastic anemia due to its suppressive effect on bone marrow function [5]. These side effects are rarely observed and can often be managed by lowering the dosage [6]. Folate and vitamin B12, another key cofactor in cell replication and erythropoiesis, may also be depleted in chronic inflammatory states. Moreover, diarrhea, a common undesirable effect of colchicine, can also cause malabsorption and micronutrient deficiencies such as iron, vitamin B12 and folate. Besides, studies in both humans and animals indicate that colchicine may interfere with vitamin B12 uptake as a result of disruption of the ileal epithelium [7]. This study aims to evaluate vitamin B12 and folate levels, along with markers of iron homeostasis, in children newly diagnosed with FMF, and to investigate whether colchicine therapy is associated with deficiencies in these essential micronutrients. Materials and methods This prospective study was conducted within the pediatric rheumatology unit of a tertiary referral hospital between October 2016 and February 2017. Children with newly diagnosed FMF who fulfilled the Tel-hashomer criteria were included in the study [8]. Demographic data, clinical features, and treatments were documented from medical charts. Patients included in the study were confirmed to be fully compliant with colchicine therapy; those with poor adherence were excluded. Patients were evaluated for serum iron, total iron binding capacity, ferritin, vitamin B12, and folate values before the initiation of colchicine treatment, then at the third and sixth months of colchicine treatment. The colchicine dose was adjusted according to the age of the patient (0.5 mg/day for 0–5 years, 1 mg/day for 5–10 years, and 1.5 mg/day over 10 years). Erythrocyte sedimentation rate (ESR), white blood cell count (WBC), C-reactive protein (CRP), hemoglobin (Hb), hematocrit (Hct), and serum amyloid A (SAA) values were recorded in every visit. Patients with coexistent disease or initial abnormal serum iron, total iron binding capacity, vitamin B12, or folate values were excluded from the study. Among the cases constituting the study group, 9 mL blood sample was taken into a 1 mL 0.5 M Ethylene permanent tetra acetic acid (EDTA) (Sigma, USA) tube; DNA was obtained from the samples prepared by mixing RBC (Red Blood Cell) [155 mM Ammonium Chloride (Appli Chem, Germany), Sodium Bicarbonate (Merck, Germany), EDTA (Appli Chem, Germany)] and Proteinase K enzyme (MBIFermentas, Lithuania). For the 2nd, 3rd, 5th, and 10th exon regions of the MEFV gene, an automated DNA sequence analysis device (Hitachi 3130XL, United States) was used, which operates based on Sanger's enzymatic sequencing method. Complete blood count tests were performed by the SYSMEX (Hamburg, Germany) brand device; vitamin B12, folate, and ferritin parameters by chemoluminescence method; iron and total iron binding capacity were studied with COBAS 6000 (Roche, USA) and COBAS 8000 (Roche, USA) brand devices with spectrophotometric methods. In the studied serum samples, 200 pg/mL and below for vitamin B12 and 2 ng/mL and below for folate were considered deficiencies [9]. Approval for the study was granted by the local Ethics Committee (decision no 2016/8; September 27, 2016), and all procedures adhered to the principles set forth in the Declaration of Helsinki. All participants were enrolled after written informed consent had been provided by their legal guardians. The SPSS (Statistical Package for Social Sciences) Windows 19.0 package program was used for statistical evaluations. Continuous variables were expressed as mean and standard deviation, while categorical variables were presented as counts and percentages. Categorically, the differences between the groups in terms of the frequencies of the data were examined by the chi-square test. The differences in mean scores between the groups were analyzed using the Mann–Whitney U test. All means with normal distribution are repeatedly measured with one-way analysis of variance and Bonferroni analysis; those without normal distribution were compared by Friedman analysis and the Wilcoxon signed rank test. For all statistical data, p < 0.05 was considered significant. Results The study included 46 children with FMF [28 male (60.9 %), 18 female (39.1 %)]. The mean age of the patients was 100.6 ± 49.7 months, with symptom onset and diagnosis occurring at 65.3 ± 45.5 months and 97.1 ± 50.2 months, respectively. More than half of the patients (n = 25, 54.3 %) had a documented family history of FMF. The M694V mutation was the predominant MEFV variant, identified in 19 cases (40.8 %). Assessment of patients’ symptoms during attack periods revealed that fever occurred in 40 individuals (86.9 %), peritonitis in 35 (76 %), pleuritis in 11 (23.9 %), and arthritis in 6 (13 %). Comparing pre-treatment and third-month data, a non-significant increase in hemoglobin (p 0.288) and a statistically significant increase in iron (p 0.007) were observed. Statistically significant decreases were observed in platelet count (p < 0.001), ferritin (p 0.001),

Read the complete text